Operating
Stock-Based Comp
Vertex Pharmaceuticals Stock-Based Comp decreased by 19.1% to $157.60M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.1%, from $167.80M to $157.60M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 11.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
An increase may signal a strategy to preserve cash or align employee interests with shareholders, but it also results in share dilution.
Detailed definition
Stock-based compensation is a non-cash expense where employees and executives are rewarded with equity or stock options...
Peer comparison
High-growth technology firms often have higher stock-based compensation as a percentage of revenue compared to mature industrial firms.
Metric ID:
cf_stock_based_compensationHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.62M | $103.00M | $118.61M | $130.30M | $113.90M | $135.60M | $111.50M | $122.40M | $119.30M | $130.90M | $208.60M | $191.90M | $154.20M | $184.60M | $167.80M | $166.10M | $167.30M | $194.90M | $157.60M |
| QoQ Change | — | -1.6% | +15.2% | +9.9% | -12.6% | +19.1% | -17.8% | +9.8% | -2.5% | +9.7% | +59.4% | -8.0% | -19.6% | +19.7% | -9.1% | -1.0% | +0.7% | +16.5% | -19.1% |
| YoY Change | — | — | — | — | +8.9% | +31.7% | -6.0% | -6.1% | +4.7% | -3.5% | +87.1% | +56.8% | +29.3% | +41.0% | -19.6% | -13.4% | +8.5% | +5.6% | -6.1% |
Range$103.00M – $208.60M
CAGR+9.5%
Avg YoY Growth+14.6%
Median YoY Growth+5.6%
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's stock-based comp?
- Vertex Pharmaceuticals (VRTX) reported stock-based comp of $157.60M in Q4 2025.
- How has Vertex Pharmaceuticals's stock-based comp changed year-over-year?
- Vertex Pharmaceuticals's stock-based comp decreased by 6.1% year-over-year, from $167.80M to $157.60M.
- What is the long-term trend for Vertex Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's stock-based comp has grown at a 11.6% compound annual growth rate (CAGR), from $441.40M to $685.90M.
- What does stock-based comp mean?
- The value of company shares given to employees as part of their pay.